LNTH News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LN

Mkt Cap

$6.52B

Volume

1.59M

Next Earnings

November 5th

Loading chart

LN

LNTHLantheus Holdings, Inc

LNTH

Pay with—

Available Balance0.00

LN

Mkt Cap

$6.53B

Volume

1.59M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed transactions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.GlobeNewswire Inc. · Sep 30, 2026

Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETsCurium announced FDA approval of BEXLUTRY, a radioligand therapy for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The approval marks Curium's first radioligand therapy and represents expansion into oncology therapeutics. The company also announced acquisitions of Abscint SA and a definitive merger agreement with Lantheus to create a global radiopharmaceutical leader.GlobeNewswire Inc. · Sep 14, 2026

Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - SNS InsiderThe radioligand therapy market is projected to grow at an 18.2% CAGR through 2035, driven by increased prostate cancer and neuroendocrine tumor cases, FDA approvals for PSMA-targeted therapies like Pluvicto, and expanded isotope production capacity. North America dominates with 80.5% market share, while Asia-Pacific is the fastest-growing region at 21.5% CAGR.GlobeNewswire Inc. · Sep 8, 2026

Halper Sadeh LLC is Investigating Whether MKTX, SMTI, LNTH are Obtaining Fair Deals for their ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.GlobeNewswire Inc. · Aug 4, 2026

Curium Announces Definitive Agreement to Merge with LantheusCurium US has agreed to acquire Lantheus Holdings for $102.50 per share in cash at closing, plus up to $12.00 per share in contingent value rights, valuing the transaction at up to $8.0 billion. The combination aims to create a comprehensive radiopharmaceutical company spanning diagnostics and therapeutics across more than 70 countries, with the deal expected to close in the first half of 2027.GlobeNewswire Inc. · Aug 3, 2026

Curium Announces Definitive Agreement to Merge with LantheusCurium US has agreed to acquire Lantheus Holdings for $102.50 per share in cash at closing, plus up to $12.00 per share in contingent value rights, valuing the transaction at up to $8.0 billion. The merger combines Curium's global theranostics platform and manufacturing capabilities with Lantheus' U.S. radiodiagnostics business, creating a combined entity serving oncology, neurology, and cardiology patients across more than 70 countries. The transaction is expected to close in the first half of 2027, subject to shareholder approval and regulatory clearances.GlobeNewswire Inc. · Aug 3, 2026

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsightThe metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.GlobeNewswire Inc. · Jun 10, 2026

Radiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market DemandThe global radiopharmaceuticals market is projected to grow from USD 8.28 billion in 2026 to USD 15.21 billion by 2035, driven by rising cancer and cardiovascular disease incidence. North America dominates with 43.95% market share, while Asia-Pacific is expected to register the fastest growth. Therapeutic radiopharmaceuticals and Technetium-99m lead their respective segments, with hospitals and clinics as the primary end users.GlobeNewswire Inc. · Apr 24, 2026

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateLantheus Holdings reported Q4 2025 revenue of $406.8 million and full-year revenue of $1.54 billion, with adjusted EPS of $1.67 and $6.08 respectively. The company announced a strategic refocus on PET radiodiagnostics and plans to pursue value-maximizing alternatives for radiotherapeutic assets. Despite PYLARIFY sales declining 9.7% in Q4, the company expects up to four FDA approvals in 2026 and provided FY2026 guidance of $1.4-1.45 billion in revenue and $5.00-5.25 adjusted EPS.GlobeNewswire Inc. · Feb 26, 2026

PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2026: PYLARIFY Exceeds US$ 1 Billion in Net Sales and Became the First Ever Blockbuster RadiodiagnosticPYLARIFY has become the first blockbuster radiodiagnostic, exceeding $1 billion in 2024 net sales with 24.3% growth. PLUVICTO, a radioligand therapeutic agent, posted $1.392 billion in 2024 sales with 42% growth. PSMA-targeted therapies and radiodiagnostics represent a clinically validated and commercially successful approach for prostate cancer treatment and diagnosis, with multiple radioligands in development.GlobeNewswire Inc. · Feb 20, 2026

to start trading

LN

LNTHLantheus Holdings, Inc

LNTH

Pay with—

Available Balance0.00

Your PositionYou don't own any LNTH yet.

Related Tickers

Earnings